Trials / Recruiting
RecruitingNCT05509933
Budesonide Prophylaxis for Engraftment Syndrome After Hematopoietic Cell Transplantation
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 110 (estimated)
- Sponsor
- Henry Ford Health System · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if budesonide prophylaxis starting day 5 after transplant reduces engraftment fever in autologous and allogeneic stem cell transplant recipients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Budesonide | budesonide starting day 5 after transplant |
Timeline
- Start date
- 2022-11-09
- Primary completion
- 2026-12-30
- Completion
- 2026-12-30
- First posted
- 2022-08-22
- Last updated
- 2025-04-29
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05509933. Inclusion in this directory is not an endorsement.